LABORATORY REPORT

Redcliffe labs

Patient Name	:	Bill Date	:
DOB/Age/Gender	:	Sample Collected	:
Patient ID / UHID	:	Sample Received	:
Referred By	:	Report Date	:
Sample Type	:	Barcode No	:
Client	:	Report Status	:

CYTOGENETICS REPORT

Karyotype : Hematological Malignancy

CLINICAL HISTORY ? CML

SUMMARY OF RESULTS **ABNORMAL KARYOTYPE WITH PHILADELPHIA CHROMOSOME (Ph)**

NOMENCLATURE **46,XX,t(9;22)(q34;q11.2) [5]**
(As per International System for Human Cytogenomic Nomenclature, ISCN,2020)

CLINICAL INTERPRETATION

An abnormal chromosome complement with a reciprocal translocation between chromosome 9 and 22, the Philadelphia chromosome (Ph), was observed in the available 05 metaphases avaialble for the analysis..The presence of the Ph is consistent with the clinical diagnosis of chronic myelogenous leukemia (CML). The Ph is present in 20% of cases of adult acute lymphocytic leukemia and in 1% of cases of acute myelogenous leukemia. In acute leukemias, the t(9;22) is regarded as an unfavorable prognostic marker. Follow-up cytogenetic monitoring by chromosome or FISH studies may be useful in assessing disease progression or monitoring the response to specific therapies, i.e., interferon, bone marrow transplantation, Gleevec.Correlation with other clinical and laboratory data is recommended.

COMMENTS Genetic /Oncologist consultation for the family is recommended.

CULTURE/SAMPLE DESCRIPTION The 24 hours/48 hours unstimulated Bone Marrow culture was setup in MarrowMAX™ (Gibco) culture media in 5% CO2. The sample was of optimal quality for conventional cytogenetics culture techniques

Dr. Ashish Fauzdar
PhD (Genetics), AIIMS
Head of Clinical Genomics & Cytogenetics

LABORATORY REPORT

Redcliffe labs

KARYOTYPE IMAGE:



LOGANAYAKI **Karyotype: 46,XX,t(9;22)(q34;q11.2)[5]** **Barcode No: CG003598**



METHOD:	G-BANDING
Metaphase Counted:	05
Metaphase Analyzed:	05
Metaphase Karyotyped:	05
Banding Resolution:	**475**
Metaphase Quality:	**Sub-Optimal**

Ms. Ritu (Jr. Scientist)
Cytogenetics

Dr. Ashish Fauzdar
PhD (Genetics), AIIMS
Head of Clinical Genomics

Reviewed and Signed out on: 14-Jun-2023

Terms and Conditions of Reporting

1. The presented findings in the Reports are intended solely for informational and interpretational purposes by the referring physician or other qualified medical professionals possessing a comprehensive understanding of reporting units, reference ranges, and technological limitations. The laboratory shall not be held liable for any interpretation or misinterpretation of the results, nor for any consequential or incidental damages arising from such interpretation.

2. It is to be presumed that the tests performed pertain to the specimen/sample attributed to the Customer's name or identification. It is presumed that the verification particulars have been cleared out by the customer or his/her representation at the point of generation of said specimen / sample. It is hereby clarified that the reports furnished are restricted solely to the given specimen only.

3. It is to be noted that variations in results may occur between different laboratories and over time, even for the same parameter for the same Customer. The assays are performed and conducted in accordance with standard procedures, and the reported outcomes are contingent on the specific individual assay methods and equipment(s) used, as well as the quality of the received specimen.

4. This report shall not be deemed valid or admissible for any medico-legal purposes.

5. The Customers assume full responsibility for apprising the Company of any factors that may impact the test finding. These factors, among others, includes dietary intake, alcohol, or medication / drug(s) consumption, or fasting. This list of factors is only representative and not exhaustive.